Calendario›REPL›RPx

RPx

A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3

Ensayo de Replimune Group, Inc. en Melanoma metastasico · Tumor solido avanzado · Carcinoma hepatocelular.

Más ensayos de: Melanoma · Melanoma metastásico · Tumor sólido avanzado · Carcinoma hepatocelular.

Fase

no aplica

Estado

Reclutando pacientes

Participantes

50

previstos

Centros

2

Fin del objetivo primario

dic 2030

estimado por el promotor

Qué significa cada fase y cada estado.

Estudio observacional. Comenzó en dic 2025.

Qué mide

Evaluate the long-term safety of patients treated with an RPx product (Every 3 months (Q3M) (± 30 days) for 5 years from enrollment on this study to assess potential delayed risks) (del registro, en inglés)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThis is a noninterventional, observational, long-term follow-up (LTFU) study. Patients in this study will be followed for 5 years from enrollment on this study to assess potential delayed risks of RPx products. Eligible participants for this LTFU study include patients who received at least 1 dose of an RPx product under the interventional parent study. Patients will be rolled over into this LTFU study after completion of the Replimune-sponsored parent study (ie, either completion of the LTFU in the parent study or withdrawal from the parent study). All patients in ongoing RPx studies will be asked to participate in this LTFU study so that the Sponsor can evaluate potential delayed risks.

Más ensayos de REPL

Todos los de REPL, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT06887348), actualizada en ene 2026.